Rationale for Nilotinib and Other Kinase Inhibitors in Parkinson’s Disease
For many months, those who follow Parkinson’s disease clinical research have been anticipating the results of a small study of the cancer drug nilotinib. The study, now published in Journal of Parkinson’s Disease,1 suggests that nilotinib and perhaps other kinase inhibitors are worthy of more serious attention as treatments for Parkinson’s and related diseases. The “related diseases” part is important here because 5 of the 12 study participants were diagnosed with dementia with Lewy bodies.